Abstract
In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.
Keywords: Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.
Current Vascular Pharmacology
Title:Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Volume: 12 Issue: 1
Author(s): Cinzia Perrino, Gabriele G. Schiattarella, Fabio Magliulo, Federica Ilardi, Giuseppe Carotenuto, Giuseppe Gargiulo, Federica Serino, Marco Ferrone, Fernando Scudiero, Andreina Carbone, Bruno Trimarco and Giovanni Esposito
Affiliation:
Keywords: Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.
Abstract: In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.
Export Options
About this article
Cite this article as:
Perrino Cinzia, Schiattarella G. Gabriele, Magliulo Fabio, Ilardi Federica, Carotenuto Giuseppe, Gargiulo Giuseppe, Serino Federica, Ferrone Marco, Scudiero Fernando, Carbone Andreina, Trimarco Bruno and Esposito Giovanni, Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/157016111201140327163302
DOI https://dx.doi.org/10.2174/157016111201140327163302 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Current In Vitro Kinase Assay Technologies: The Quest for a Universal Format
Current Drug Discovery Technologies Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology